Myelodysplastic Syndromes
"Myelodysplastic Syndromes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Descriptor ID |
D009190
|
MeSH Number(s) |
C15.378.190.625
|
Concept/Terms |
Myelodysplastic Syndromes- Myelodysplastic Syndromes
- Myelodysplastic Syndrome
- Syndrome, Myelodysplastic
- Syndromes, Myelodysplastic
- Dysmyelopoietic Syndromes
- Dysmyelopoietic Syndrome
- Syndrome, Dysmyelopoietic
- Syndromes, Dysmyelopoietic
Hematopoetic Myelodysplasia- Hematopoetic Myelodysplasia
- Hematopoetic Myelodysplasias
- Myelodysplasia, Hematopoetic
- Myelodysplasias, Hematopoetic
|
Below are MeSH descriptors whose meaning is more general than "Myelodysplastic Syndromes".
Below are MeSH descriptors whose meaning is more specific than "Myelodysplastic Syndromes".
This graph shows the total number of publications written about "Myelodysplastic Syndromes" by people in this website by year, and whether "Myelodysplastic Syndromes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 2 | 1 | 3 |
1996 | 8 | 0 | 8 |
1997 | 5 | 2 | 7 |
1998 | 1 | 1 | 2 |
1999 | 1 | 2 | 3 |
2000 | 5 | 1 | 6 |
2001 | 2 | 0 | 2 |
2002 | 9 | 1 | 10 |
2003 | 3 | 2 | 5 |
2004 | 2 | 1 | 3 |
2005 | 5 | 1 | 6 |
2006 | 3 | 0 | 3 |
2007 | 4 | 2 | 6 |
2008 | 3 | 1 | 4 |
2009 | 10 | 4 | 14 |
2010 | 4 | 1 | 5 |
2011 | 6 | 0 | 6 |
2012 | 7 | 0 | 7 |
2013 | 8 | 1 | 9 |
2014 | 9 | 1 | 10 |
2015 | 10 | 0 | 10 |
2016 | 9 | 4 | 13 |
2017 | 12 | 2 | 14 |
2018 | 7 | 1 | 8 |
2019 | 7 | 0 | 7 |
2020 | 8 | 1 | 9 |
2021 | 3 | 1 | 4 |
2022 | 9 | 0 | 9 |
2023 | 13 | 0 | 13 |
2024 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myelodysplastic Syndromes" by people in Profiles.
-
Insights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene-Environment Interactions. Cancer Discov. 2024 Mar 01; 14(3):396-405.
-
Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML. Blood Adv. 2024 02 13; 8(3):553-561.
-
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024 Jan; 11(1):e15-e26.
-
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Ann Hematol. 2024 Jan; 103(1):105-116.
-
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023 Dec; 10(12):e994-e1005.
-
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev. 2023 11; 62:101128.
-
From cell surface to nucleus: CCRL2 regulates response to hypomethylating agents in myelodysplastic syndromes. Haematologica. 2023 Jul 01; 108(7):1729-1730.
-
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood Adv. 2023 Jun 27; 7(12):2709-2714.
-
The Times, They Are A-Changing: The Impact of Next-Generation Sequencing on Diagnosis, Classification, and Prognostication of Myeloid Malignancies With Focus on Myelodysplastic Syndrome, AML, and Germline Predisposition. Am Soc Clin Oncol Educ Book. 2023 Jun; 43:e390026.
-
Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group. Leuk Res. 2023 07; 130:107309.